Cargando…

24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent

PURPOSE: The purpose of the study is to report 24-month efficacy and safety results for the Japanese patient cohort in a prospective randomized controlled trial (RCT) of drug-eluting stent (DES) use for peripheral artery disease. MATERIALS AND METHODS: Patients in the global IMPERIAL RCT had femorop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iida, Osamu, Fujihara, Masahiko, Kawasaki, Daizo, Mori, Shinsuke, Yokoi, Hiroyoshi, Miyamoto, Akira, Kichikawa, Kimihiko, Nakamura, Masato, Ohki, Takao, Diaz-Cartelle, Juan, Müller-Hülsbeck, Stefan, Gray, William A., Soga, Yoshimitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382620/ https://www.ncbi.nlm.nih.gov/pubmed/34235560 http://dx.doi.org/10.1007/s00270-021-02901-6

Ejemplares similares

One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease
por: Soga, Yoshimitsu, et al.
Publicado: (2020)

Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results
por: Kichikawa, Kimihiko, et al.
Publicado: (2018)

Zilver PTX RCT mortality analysis: no difference in long-term mortality rate for Zilver PTX drug-eluting stent compared to PTA/BMS
por: Dake, Michael D., et al.
Publicado: (2019)

Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan
por: Ogawa, Yukihisa, et al.
Publicado: (2017)

Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease
por: Müller-Hülsbeck, Stefan, et al.
Publicado: (2016)

Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices
por: Dake, Michael D., et al.
Publicado: (2019)

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
por: Dake, Michael D., et al.
Publicado: (2016)

First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study
por: Ye, Wei, et al.
Publicado: (2022)

Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent
por: Dake, Michael D., et al.
Publicado: (2020)

Impact of postprocedural minimum lumen area on clinical outcome after femoropopliteal drug-eluting stent implantation
por: Haraguchi, Takuya, et al.
Publicado: (2023)

ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results
por: Bosiers, Michel J., et al.
Publicado: (2023)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Incidence and Clinical Impact of Stent Fracture After the Nobori Biolimus‐Eluting Stent Implantation
por: Kuramitsu, Shoichi, et al.
Publicado: (2014)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

“Low Echoic Area” around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease
por: Soga, Yoshimitsu, et al.
Publicado: (2021)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Optimization of Drug Delivery by Drug-Eluting Stents
por: Bozsak, Franz, et al.
Publicado: (2015)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Advances in drug eluting stents – focus on the Endeavor(®) zotarolimus stent
por: Bridges, Jonathan, et al.
Publicado: (2008)

Drug-eluting metallic stents in urology
por: Kallidonis, Panagiotis S., et al.
Publicado: (2014)

Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis
por: Chen, Yun-lin, et al.
Publicado: (2019)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Drug Release Analysis and Optimization for Drug-Eluting Stents
por: Li, Hongxia, et al.
Publicado: (2013)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation
por: Jeon, Doo-Soo, et al.
Publicado: (2010)

Pathogenesis of late in-stent thrombosis after treatment with drug-eluting stents
por: Hao, Hiroyuki
Publicado: (2012)

Drug-Eluting Stent: A Review and Update
por: Htay, Thein, et al.
Publicado: (2005)

Pathological Perspective of Drug-Eluting Stent Thrombosis
por: Inoue, Katsumi
Publicado: (2012)

Functional Nanoarchitectures For Enhanced Drug Eluting Stents
por: Saleh, Yomna E., et al.
Publicado: (2017)

Drug-eluting stents: insights into safety and indications
por: Hassan, Walid
Publicado: (2008)

Are Drug Eluting Stents Worth Triple Therapy?
por: Heidenreich, Paul
Publicado: (2017)

Drug-Eluting Stents: Technical and Clinical Progress
por: Koźlik, Maciej, et al.
Publicado: (2023)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment
por: Tacke, Josef, et al.
Publicado: (2019)

In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation
por: Kato, Yuta, et al.
Publicado: (2017)

Local drug-delivery balloon for proliferative occlusive in-stent restenosis after drug-eluting stent
por: Rigatelli, Gianluca, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_haoelqh2bh71dg491o5gqfdn53